NXTC NextCure, Inc.

36.07-2.48 (-6.43%)
IEX price: 3:59:51 PM

Quote

Previous Close
-
Day Range
-
52 Week Range
$13.86-$109.00
Volume
2,106,238
Avg Volume
629,423
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$820.74M
Enterprise Value (EV)
$740.49M
PE Ratio
-
EV/EBITDA
-34.41
Price/Sales
-
Price/Book
7.61
PEG Ratio
-

Financials

Revenue
-
Gross Profit
-$1.68M
EBITDA
-$21.52M
EPS, ttm
-
Profit Margin
-
Revenue/Employee
-
Next Earnings Date
2/26/2020 (103 days)
Debt to Equity
-
Debt
$55.39M
Cash
$135.63M
Net Debt
-

Performance

Beta
-1.42
200 Day Moving Avg
$26.45
50 Day Moving Avg
$35.73
52 Week Change
93.72%
YTD Change
87.29%
1 Month Change
42.04%
3 Month Change
49.71%
6 Month Change
92.65%
1 Year Change
93.72%
2 Year Change
93.72%
5 Year Change
93.72%

Share Count

Shares Outstanding
22.7M
Float
12.4M
Restricted Shares
10.3M
Restricted Shares, %
45.46%

NextCure, Inc. Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Michael S. Richman

Website: http://www.nextcure.com

Description: NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lieping Chen in September 2015 and is headquartered in Beltsville, MD.

Employees: 44